Cargando…

Increased Risk of Persistent Glucose Disorders After Control of Acromegaly

PURPOSE: Combining surgery and medical treatments allows the control of growth hormone hypersecretion in 80% of cases. Our objective was to determine the rate of acromegaly comorbidities once hypersecretion of growth hormone is controlled. METHODS: Our retrospective monocentric study was based on 13...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochette, Claire, Graillon, Thomas, Albarel, Frederique, Morange, Isabelle, Dufour, Henry, Brue, Thierry, Castinetti, Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740518/
https://www.ncbi.nlm.nih.gov/pubmed/29308447
http://dx.doi.org/10.1210/js.2017-00334
Descripción
Sumario:PURPOSE: Combining surgery and medical treatments allows the control of growth hormone hypersecretion in 80% of cases. Our objective was to determine the rate of acromegaly comorbidities once hypersecretion of growth hormone is controlled. METHODS: Our retrospective monocentric study was based on 130 patients followed on a regular basis, with acromegaly controlled by medical treatments or cured by surgery or radiation technique. Our main outcome measures were the prevalence of major metabolic complications of acromegaly (diabetes, hypertension, low-density lipoprotein cholesterol, triglycerides) at diagnosis and last follow-up in comparison with French epidemiological data. RESULTS: As expected, controlling hypersecretion significantly improved the metabolic complications of acromegaly. However, the proportion of patients having at least one metabolic complication of acromegaly at last follow-up (mean, 72 months after remission) was 27% for altered glucose tolerance or diabetes, 39% for hypertension, 34.3% for hypercholesterolemia, and 13.3% for hypertriglyceridemia. Interestingly, our data showed that diabetes was the only comorbidity different with a higher prevalence in patients in remission versus a general population of a similar median age (21.6% vs 6.9%, respectively). CONCLUSIONS: The follow-up of glucose disorders needs to be maintained on a long-term basis in patients controlled for acromegaly.